Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11

Virology Journal

Volumn 3, Issue , 2006, Pages

  Van Rompay, Koen K A ^a   Blackwood, Emily J ^a   Landucci, Gary ^b   Forthal, Don ^b   Marthas, Marta L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; INOCULATION; MACACA; MOLECULAR CLONING; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON-ALPHA; INTERLEUKIN-12; KILLER CELLS, NATURAL; MACACA; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS REPLICATION;

ANIMALIA; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33746021678     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-22     Document Type: Article

References (33)

1. Staprans SI, Feinberg MB: The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004, 3(4 Suppl):S5-32.
2. Haigwood NL: Predictive value of primate models for AIDS. AIDS Reviews 2004, 6(4):187-198.
3. Van Rompay KKA: Antiretroviral drug studies in non-human primates: a valid animal model for innovative drug efficacy and pathogenesis studies . AIDS Reviews 2005, 7:67-83.
4. Marthas ML, Banapour B, Sutjipto S, Siegel ME, Marx PA, Gardner MB, Pedersen NC, Luciw PA: Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus. Journal of Medical Primatology 1989, 18:311-319.
5. Luciw PA, Shaw KE, Unger RE, Planelles V, Stout MW, Lackner JE, Pratt-Lowe E, Leung NJ, Banapour B, Marthas ML: Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses 1992, 8(3):395-402.
6. Banapour B, Marthas ML, Munn RJ, Luciw PA: In vitro macrophage tropism of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus. Virology 1991, 183:12-19.
7. Tarantal AF, Marthas ML, Gargosky SE, Otsyula M, McChesney MB, Miller CJ, Hendrickx AG: Effects of viral virulence on intrauterine growth in SIV-infected fetal rhesus macaques Macaca mulatta. J Acquir Immun Defic Syndr Hum Retrovirol 1995, 10(2):129-138. Oct 1
8. Marthas ML, Van Rompay KKA, Otsyula M, Miller CJ, Canfield D, Pedersen NC, McChesney MB: Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. Journal of Virology 1995, 69(7):4198-4205.
9. Lackner AA, Vogel P, Ramos RA, J. D. Kluge JD, Marthas M: Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. American Journal of Pathology 1994, 145(2):428-439.
10. Marthas ML, Ramos RA, Lohman BL, Van Rompay KKA, Unger RE, Miller CJ, Banapour B, Pedersen NC, Luciw PA: Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J Virol 1993, 67(10):6047-6055.
11. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, Pedersen NC: Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 1990, 64(8):3694-3700.
12. Van Rompay KKA, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, Pahar B, Rourke T, Montelaro RC, Canfield DR, Tarara RP, Miller CJ, McChesney MB, Marthas ML: Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. Journal of Virology 2003, 77:179-190.
13. Otsyula MG, Miller CJ, Tarantal AF, Marthas ML, Greene TP, Collins JR, Van Rompay KKA, McChesney MB: Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology 1996, 222:275-278.
14. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA: Control of viremia in simian immunodeficiency virus infection by CD8+ T lymphocytes. Science 1999, 283:857-860.
15. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, Perelson AS, Marx PA, Ho DD, Kostrikis LG, Connor RI: Effects of in vivo CD8+ depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. Journal of Experimental Medicine 2000, 191(11):1921-1931.
16. Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, Kuroda MJ, Lifton MA, Khunkhun RS, McEvers KJ, Gillis J, Piatak M, Lifson JD, Grosschupff G, Racz P, Tenner-Racz K, Rieber EP, Kuus-Reichel K, Gelman RS, Letvin NL, Montefiori DC, Ruprecht RM, Desrosiers RC, Reimann KA: Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005, 79(13):8131-8141.
17. National Research Council: Guide for the care and use of laboratory animals. Washington, D. C. , National Academy Press; 1996.
18. Van Rompay KKA, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N: CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. Journal of Virology 2004, 78:5324-5337.
19. Miller CJ, Marthas M, Greenier J, Lu D, Dailey P, Lu Y: In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. Journal of Virology 1998, 72(4):3248-3258.
20. Abel K, Compton L, Rourke T, Montefiori D, Lu D, Rothaeusler K, Fritts L, Bost K, Miller CJ: Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. Journal of Virology 2003, 77(5):3099-3118.
21. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI: Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002, 76(14):7187-7202.
22. Lifson JD, Piatak MJ, Cline AN, Rossio JL, Purcell J, Pandrea I, Bischofberger N, Blanchard J, Veazey RS: Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 2003, 32(4-5):201-210.
23. Bernstein HB, Kinter AL, Jackson R, Fauci AS: Neonatal natural killer cells produce chemokines and suppress HIV replication in vitro. AIDS Res Hum Retroviruses 2004, 20(11):1189-1195.
24. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW, Fauci AS: Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. Journal of Clinical Investigation 1998, 102(1):223-231.
25. Dines I, Rumjanek VM, Persechini PM: What is going on with natural killer cells in HIV infection? Int Arch Allergy Immunol 2004, 133(4):330-339.
26. Brenner BG, Gryllis C, Wainberg MA: Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991, 50(6):628-640.
27. Forthal DN, Landucci G, Daar ES: Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural killer effector cells. Journal of Virology 2001, 75(15):6953-6961.
28. Forthal DN, Landucci G, Phan TB, Becerra J: Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005, 79(4):2042-2049.
29. Van Rompay KKA, Singh R, Brignolo L, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Bischofberger N, Marthas M: The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. Journal of Acquired Immune Deficiency Syndromes 2004, 36(4):900-914.
30. Veazey RS, Lackner AA: Getting to the guts of HIV pathogenesis. J Exp Med 2004, 200(6):697-700.
31. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434(7037):1148-1152.
32. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434(7037):1093-1097.
33. Van Rompay KKA, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, Pedersen NC: Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992, 36(11):2381-2386.